KURA ONCOLOGY, INC. Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31)
KURA ONCOLOGY, INC. (KURA) reported Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) of $0 for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefitContinuingOperations · last filed 2013-03-28
- KURA ONCOLOGY, INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2012 was $0.00.
- KURA ONCOLOGY, INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2011 was $0.00.
| Period end | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 12 month |
|---|---|
| 2012-12-31 | $0.00 10-K · filed 2013-03-28 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |